Chris Schott
Stock Analyst at J.P. Morgan
(4.28)
# 1,414
Out of 4,639 analysts
659
Total ratings
57.9%
Success rate
6%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintained: Buy | n/a | $22.73 | - | 23 | Aug 11, 2026 | |
| VTRS Viatris | Maintained: Hold | $18 | $16.28 | +10.57% | 29 | Aug 10, 2026 | |
| ZTS Zoetis | Maintained: Buy | $130 → $115 | $75.35 | +52.62% | 16 | Aug 10, 2026 | |
| RPRX Royalty Pharma | Maintained: Buy | $58 → $62 | $57.79 | +7.29% | 10 | Aug 10, 2026 | |
| AMGN Amgen | Maintained: Hold | $300 → $350 | $414.30 | -15.52% | 12 | Aug 6, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,400 | $1,215.02 | +15.22% | 72 | Aug 6, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $160 | $135.77 | +17.85% | 34 | Aug 6, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $140 → $150 | $130.42 | +15.01% | 35 | Aug 6, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Buy | $73 | $63.61 | +14.76% | 42 | Aug 4, 2026 | |
| PFE Pfizer | Maintained: Hold | $28 | $26.62 | +5.18% | 90 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $850 → $900 | $797.00 | +12.92% | 32 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $185 → $210 | $203.89 | +3.00% | 20 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $260 → $270 | $259.80 | +3.93% | 20 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $280 | $250.09 | +11.96% | 38 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $36.48 | - | 43 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $17.10 | +5.26% | 19 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 → $15 | $12.85 | +16.73% | 31 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 → $11 | $13.65 | -19.41% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $675 → $775 | $586.64 | +32.11% | 15 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 → $8 | $1.21 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.68 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.07 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €83.08 → €84.82 | €138.75 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 → $54 | $24.38 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.844899 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.01 | n/a | 1 | Oct 17, 2013 |
Elanco Animal Health
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $22.73
Upside: -
Viatris
Aug 10, 2026
Maintained: Hold
Price Target: $18
Current: $16.28
Upside: +10.57%
Zoetis
Aug 10, 2026
Maintained: Buy
Price Target: $130 → $115
Current: $75.35
Upside: +52.62%
Royalty Pharma
Aug 10, 2026
Maintained: Buy
Price Target: $58 → $62
Current: $57.79
Upside: +7.29%
Amgen
Aug 6, 2026
Maintained: Hold
Price Target: $300 → $350
Current: $414.30
Upside: -15.52%
Eli Lilly and Company
Aug 6, 2026
Rated: Buy
Price Target: $1,400
Current: $1,215.02
Upside: +15.22%
Gilead Sciences
Aug 6, 2026
Maintained: Buy
Price Target: $160
Current: $135.77
Upside: +17.85%
Merck & Co.
Aug 6, 2026
Maintained: Buy
Price Target: $140 → $150
Current: $130.42
Upside: +15.01%
Bristol-Myers Squibb Company
Aug 4, 2026
Maintained: Buy
Price Target: $73
Current: $63.61
Upside: +14.76%
Pfizer
Aug 4, 2026
Maintained: Hold
Price Target: $28
Current: $26.62
Upside: +5.18%
Aug 4, 2026
Maintained: Buy
Price Target: $850 → $900
Current: $797.00
Upside: +12.92%
Jul 30, 2026
Maintained: Hold
Price Target: $185 → $210
Current: $203.89
Upside: +3.00%
Jul 16, 2026
Rated: Hold
Price Target: $260 → $270
Current: $259.80
Upside: +3.93%
Jul 9, 2026
Rated: Buy
Price Target: $280
Current: $250.09
Upside: +11.96%
Jun 15, 2026
Maintained: Buy
Price Target: n/a
Current: $36.48
Upside: -
Mar 2, 2026
Maintained: Buy
Price Target: $18
Current: $17.10
Upside: +5.26%
Feb 27, 2026
Maintained: Hold
Price Target: $18 → $15
Current: $12.85
Upside: +16.73%
Feb 13, 2026
Maintained: Sell
Price Target: $12 → $11
Current: $13.65
Upside: -19.41%
Nov 3, 2025
Maintained: Buy
Price Target: $675 → $775
Current: $586.64
Upside: +32.11%
May 25, 2023
Maintained: Hold
Price Target: $9 → $8
Current: $1.21
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $8.68
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $2.07
Upside: n/a
Mar 9, 2020
Maintained: Buy
Price Target: €83.08 → €84.82
Current: €138.75
Upside: n/a
Feb 20, 2020
Maintained: Hold
Price Target: $43 → $54
Current: $24.38
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Nov 17, 2017
Maintained: Buy
Price Target: $35
Current: $0.844899
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $14.01
Upside: n/a